Consensus Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
9.19 ^USD	-5.94%		-0.65%	-46.10%

May. 07	Neumora Therapeutics Shares Fall as Q1 Loss Narrows	MT
May. 07	Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Neumora Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3e18f784dac3ceb4.b8uMCl3nbh3VehNDK7lTMf1_o08XSyzfudPjSuZQg-0.CbLpTzCpGSmvTUcFZ-42SKUeyAV8OEuq7qekLoc1t6kgou5ZBYwBcuIDZA~c30310e53ab00b88a37b41dc1498b254

Analyst Recommendations on Neumora Therapeutics, Inc.

JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	Mar. 18	MT
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk	Mar. 08	MT
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target	Dec. 12	MT
JPMorgan Initiates Neumora Therapeutics at Overweight Rating With $21 Price Target	23-10-10	MT
BofA Securities Initiates Neumora Therapeutics at Buy Rating	23-10-10	MT
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder	23-10-10	MT
Guggenheim Starts Neumora Therapeutics at Buy With $22 Price Target	23-10-10	MT
William Blair Starts Neumora Therapeutics With Outperform Rating	23-10-10	MT
BofA Securities Starts Neumora Therapeutics With Buy Rating	23-10-10	MT
Stifel Starts Neumora Therapeutics at Buy	23-10-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.19 USD

Average target price

24.51 USD

Spread / Average Target

+166.68%

High Price Target

29 USD

Spread / Highest target

+215.56%

Low Price Target

22 USD

Spread / Lowest Target

+139.39%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neumora Therapeutics, Inc.

JPMorgan Chase
RBC Capital Markets
Deutsche Bank Securities
BofA Securities
Guggenheim
Stifel Nicolaus
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar